D
Keros Therapeutics, Inc. KROS
$14.07 $0.030.21% NASDAQ
Recommendation
Prev Close
$14.14
Volume
115,276
Avg Vol (90D)
1,312,265
Market Cap
$574.30M
Dividend & Yield
--
52-Week Range
$9.12 - $72.37
P/E (TTM)
--
EPS (TTM)
-$1.59
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Keros Therapeutics (KROS, $14.14) entered Uptrend as Momentum indicator ascends above 0 level on May 20, 2025
5/21/2025 - Tickeron - Technical Analysis
ADAR1 Announces ISS Recommends Keros Therapeutics Stockholders WITHHOLD Votes from Directors Dr. ...
5/21/2025 - GuruFocus
ADAR1 Announces ISS Recommends Keros Therapeutics Stockholders WITHHOLD Votes from Directors Dr. ...
5/21/2025 - GuruFocus
ADAR1 Announces ISS Recommends Keros Therapeutics Stockholders WITHHOLD Votes from Directors Dr. Mary Ann Gray and Dr. Alpna Seth
5/21/2025 - PR Newswire
Tema Etfs LLC Purchases Shares of 35,663 Keros Therapeutics, Inc. (NASDAQ:KROS)
5/20/2025 - MarketBeat
TFG Asset Management GP Ltd Invests $1.63 Million in Keros Therapeutics, Inc. (NASDAQ:KROS)
5/20/2025 - MarketBeat
Keros Therapeutics Highlights Commitment to Maximizing Stockholder Value
5/19/2025 - GuruFocus
Keros Therapeutics urges stockholders to vote for company's director nominees
5/19/2025 - The Fly
Keros Therapeutics Highlights Commitment to Maximizing Stockholder Value
5/19/2025 - Globe Newswire
TFG Asset Management GP Ltd Invests $1.63 Million in Keros Therapeutics, Inc. (NASDAQ:KROS)
5/18/2025 - Ticker Report
Scotiabank Lowers Keros Therapeutics (NASDAQ:KROS) Price Target to $26.00
5/14/2025 - MarketBeat
Parkman Healthcare Partners LLC Sells 107,241 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS)
5/14/2025 - Ticker Report
Keros Therapeutics' (NASDAQ:KROS) Earnings May Just Be The Starting Point
5/14/2025 - Simply Wall St
Integral Health Asset Management LLC Purchases 250,000 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS)
5/14/2025 - MarketBeat
Balyasny Asset Management L.P. Lowers Position in Keros Therapeutics, Inc. (NASDAQ:KROS)
5/14/2025 - MarketBeat
Q2 EPS Estimate for Keros Therapeutics Increased by Analyst
5/13/2025 - MarketBeat
KROS: ADAR1 Capital Opposes Board Re-election at Keros Therapeutics KROS Stock News
5/12/2025 - GuruFocus
Scotiabank Adjusts Price Target for Keros Therapeutics (KROS) KROS Stock News
5/12/2025 - GuruFocus
ADAR1 Capital Management Releases Investor Presentation Outlining Its Rationale for Withholding Votes From Directors Dr. Mary Ann Gray and Dr. Alpna Seth
5/12/2025 - PR Newswire
Scotiabank Lowers Keros Therapeutics (NASDAQ:KROS) Price Target to $26.00
5/12/2025 - Ticker Report
Keros Therapeutics (KROS) Price Target Cut to $26 by Scotiabank KROS Stock News
5/12/2025 - GuruFocus
Keros Therapeutics price target lowered by $15 at Scotiabank, here's why
5/12/2025 - The Fly
Keros Therapeutics Announces Participation at Bank of America 2025 Global Healthcare Conference
5/12/2025 - GuruFocus
Keros Therapeutics Announces Participation at Bank of America 2025 Global Healthcare Conference
5/12/2025 - Globe Newswire
Leerink Partnrs Has Negative Estimate for KROS Q2 Earnings
5/11/2025 - MarketBeat
Income Statement
Total Revenue (TTM)
$214.71M
EBITDA (TTM)
-$9.01M
EBIT (TTM)
-$10.31M
Net Income (TTM)
$4.21M
Balance Sheet
Total Assets (Q)
$784.56M
Total Debt (Q)
$18.41M
Total Liabilities (Q)
$55.69M
Book Value Per Share (Q)
$17.97
Cash Flow
Cash from Operations (TTM)
$44.86M
Cash from Investing (TTM)
-$1.55M
Cash from Financing (TTM)
$235.02M
Net Change in Cash (TTM)
$278.34M
Filings
Filing Date
Tuesday, May 6, 2025
Period Date
Monday, March 31, 2025
Next Filing
Week of Aug 4 and 8 (est)
Price History
Loading...
Beta
0.92
7-Day Total Return
2.40%
30-Day Total Return
44.16%
60-Day Total Return
29.02%
90-Day Total Return
-3.37%
Year to Date Total Return
-11.62%
1-Year Total Return
-72.10%
2-Year Total Return
-71.24%
3-Year Total Return
-61.31%
5-Year Total Return
-48.50%
52-week Low
Apr 09, 2025 - $9.12
52-week High
Dec 09, 2024 - $72.37
Valuation
Market Cap
$574.30M - Small Cap
Enterprise Value
-$127.83M
Price/Sales (TTM)
2.70
Price/Book (Q)
0.79
Dividends and Shares
Shares Outstanding
41.02M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.kerostx.com
Phone Number
617 314 6297
Address
1050 Waltham Street
Lexington, MA 02421
Country
United States
Year Founded
2015
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the... more
NASDAQ 05/22/2025 12:54PM Eastern Quotes delayed